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Abstract In an attempt to study the functional similarities 
between protein kinase C from the yeast Saccharomyces 
cerevisiae and its human homologues we have started in vitro 
mutagenesis to alter specific domains. Here we report on the 
exchange of four cysteine residues by serines in yeast Pkclp that 
have been shown to be essential for diacylglycerol (DAG) binding 
and activation by this compound in humans. The mutant yeast 
protein leads to sensitivity to caffeine and low concentrations of 
SDS when expressed in a pkcl deletion strain. However, 
sensitivity to staurosporine was not affected. Our data indicate 
that the conserved DAG binding domain serves an important 
function in yeast Pkclp. 
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1. Introduction 
Protein kinase C (Pkc) is an important component of signal 
transduction pathways from yeast to man [1]. Its medical 
importance is exemplified by the fact that phorbol esters, 
which activate Pkc in analogy to the natural activator dia-
cylglycerol (DAG), act as tumor promoters in humans [2]. 
In yeast, protein kinase C has been shown to be part of a 
regulatory MAP kinase cascade essential for cellular integrity 
and response to low osmolarity environments [3]. Earlier re-
ports on kinetic parameters of the yeast enzyme [4,5] have 
been questioned after cloning, sequencing and deletion of 
the encoding gene [6]. Deletions in pkcl are lethal in the 
absence of osmotic stabilization [7,8]. A lytic phenotype in 
the absence of osmotic stabilizers, at least at higher temper-
atures, is also characteristic for deletion mutants affecting 
most of the downstream components of the pathway, which 
by themselves are activated by a phosphorylation cascade [9]. 
As a direct target of Pkclp, Bcklp protein has been identified 
by isolation of suppressor mutants [10]. It in turn phosphoryl-
ates Mkklp/Mkk2p (the MAP kinase kinases [11]) that act 
on Mpklp (= Slt2p), the actual MAP kinase of the pathway 
[12]. Recently, the MADS box protein Rlmlp and the SBF 
transcription complex (composed of Swi4p and Swi6p) have 
been shown to be targets of the latter [13,14]. 
The structure and function of Pkclp in yeast have been 
studied by both biochemical and genetic means. Thus, four 
functional domains have been postulated in the primary se-
quence (compare also Fig. 1). The C-terminal part of the 
protein contains the actual kinase domain, responsible for 
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phosphorylation of the target protein Bcklp. This function 
can be blocked by another domain of Pkclp that is localized 
in the N-terminal part and described to be a pseudosubstrate 
site [15]. Between these, two motifs, called Cl and C2, pre-
sumably binding DAG and calcium, can be found, with dis-
tinct homologies to the mammalian Pkc protein [6]. Finally, a 
long N-terminal, yeast-specific, extension of about 390 amino 
acids in Pkclp as compared to the mammalian counterpart 
could be involved in specific regulatory functions. Similar se-
quences can also be found in the homologous proteins from 
Schizosaccharomyces pombe [16,17] and Candida albicans [18]. 
Pkclp RHOl [19,20], a small G-protein, was identified as 
an upstream component for the activation of yeast. This in 
turn is controlled by a variety of proteins, with their encoding 
genes discovered in genetic screens, such as TOR2 [21], ROM1 
and ROM2 [22]. Despite this progress, the role of DAG in the 
activation of yeast Pkclp remains a point of ambiguity. Thus, 
in contrast to the mammalian system, biochemical data indi-
cate that the enzyme is activated neither by DAG itself, nor 
by phorbol esters [15]. On the other hand, sequence analyses 
clearly show a conservation in the DAG binding site of yeast 
Pkclp as compared to the human enzyme (see above). In 
addition, increased DAG levels have been found in a yeast 
cdc28 mutant, where Cdc28p is thought to be involved in 
Pkclp activation [23]. These data suggest a role of DAG in 
activation of yeast Pkclp similar to the function in human 
cells. To address this question, we started in vitro mutagene-
sis, exchanging conserved amino acids in the putative DAG 
binding site of the yeast enzymes. 
2. Materials and methods 
2.1. Media and culture conditions 
Rich media were based on 1% yeast extract and 2% bacto peptone 
(Difco) and supplemented with 2% glucose (YEPD) or 2% galactose. 
Yeast transformants were selected on minimal medium (0.67% yeast 
nitrogen base, 2% glucose) supplemented with amino acids and bases, 
lacking leucine or tryptophan as described [24]. For preparation of 
screening media, SDS from a 10% stock solution, sterile calcofluor 
white solution (final concentration 1.5 mg/ml) or sterile caffeine from 
a 100 mM stock solution was added to YEPD as indicated. 
For growth of Escherichia coli, standard LB media with addition of 
the appropriate antibiotics were employed [25]. 
2.2. Strains 
Saccharomyces cerevisiae strain HD56-5A (MATa urai-52 leu2-
3,112 his3-ll,15 MAL SUC GAL [26]), and its isogenic diploid deriv-
ative DHD5 were used for most of the work described. VW1A 
(MATa ura3-52 leu2-3,112 his3Dl trpl-289 MAL2-8C SUC2 GAL 
[27]) was used as a recipient strain for determination of stabilities of 
the tagged Pkclp proteins (see below). DHD5Apkc (MATala 
Aplccl::HIS3IPKCl ura3-52lura3-52 Ieu2-3,112lleu2-3,112 his3-ll,15l 
his3-ll,15 MALIMAL SUCISUC GAL/GAL) was constructed in this 
work as a diploid recipient strain. It contains a substitution of one of 
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the PKC1 alleles by the HIS3 marker, where bases 723-3170 relative 
to the ATG translation start codon have been deleted. 
For work with E. coli, strain DH5aF' (Gibco BRL) was used 
throughout. 
2.3. Plasmids used 
To construct a yeast vector carrying the complete PKC1 coding 
region and its flanking sequences, a 4.2 kbp genomic SphI fragment 
from strain VW1A was cloned into YCplacl 11 [28]. The fragment was 
obtained by PCR using the primers 5'-GGCTTCGCATCG-
CATCGC-3' and 5'-ATGGGACGCAATCACGC-3'. The resulting 
vector was called YCpPKCl. 
For in vitro mutagenesis of PKC1, the Xbal/Pstl fragment from 
YCpPKCl was cloned into pUC18 and pUC19 ([29], as a second 
Xbal site at position 2157 of the PKC1 coding sequence is protected 
by methylation in E. coli). The resulting plasmids were called pHPSlO 
and pHPSll, respectively. For recloning of the mutagenized frag-
ments, YCpPKCl was digested with Aspl\%ISaK, filled in with Kle-
now fragment of DNA polymerase I and religated to remove the Xbal 
site from the polylinker. This resulted in plasmid pHPS13. The prod-
ucts of the PCR mutagenesis were then cloned as Xbal fragments into 
pUC19 [29], to generate plasmids pHPS17 (mutation in the second 
DAG binding site) and pHPS18 (mutation in the first DAG binding 
site). 
The mutation in the first binding site was liberated as an XballNcol 
fragment from pHPS18, the mutation in the second binding site as a 
Bamill/Ncol fragment from pHPS17. Each of the fragments sub-
cloned was sequenced in the vectors they originated from. Both frag-
ments were ligated together with the large fragment of pHPS13 di-
gested with BamHVXbal. This resulted in pHPS23. 
For epitope tagging of wild-type and mutant PKC1, PCR reactions 
with either pHPS13 or pHPS23 as templates and the primers 5'-
GCGAGATCTGGGAGCAGTTTACAG-3' and 5'-AACAGCTAT-
GACCATG-3' (Ml3 reverse sequencing primer) were performed. 
The first primer introduced a BgKl site (underlined) directly in front 
of the translational start codon of PKC1. Products were then digested 
with BgUVSphl and inserted into the polylinker region of pUK21 [30], 
From these plasmids, called pHPS27 and pHPS28, respectively, the 
BamHIINotl fragment was cloned into the BgKl/Notl digested vector 
YCpIF17 [31] which resulted in an N-terminal fusion of Pkclp to the 
hemagglutinin epitope of hemophilus influenza. 
2.4. Genetic manipulations, transformations and DNA preparations 
E. coli was transformed by the method of Hanahan and Glover 
[32]. Yeasts were transformed by a variation of the freeze method 
[33]. Plasmid DNA was prepared from E. coli either by alkaline lysis 
[34] or with the kit of Qiagen (Dusseldorf), according to the instruc-
tions of the manufacturer. 
Other genetic engineering techniques followed standard procedures 
[25]. 
2.5. Sequence analysis 
Sequencing was performed by the dideoxy-chain termination meth-
od [35], using the Sequenase version 2.0 from USB in conjunction 
with [35S]dATP. The universal and reverse sequencing primers as 
well as custom-made oligonucleotides (from MWG, Munich) were 
used. 
2.6. In vitro mutagenesis of PKC1 
For in vitro mutagenesis of PKC1 we followed the PCR-based 
method of Boles and Miosga [36] using the primers 5'-GGTATACT-
GGGTTCCAATcTCAAGATTcTAAATTTTTATGTCAC-3' and 5'-
TACCAgATTCAGAAgATTTGCGTACTTTATGTC-3' (bases dif-
fering from the wild-type sequence are depicted in lower case letters) 
and pHPSlO or pHPSll as templates. 
2.7. Immunoblot analyses 
Preparation of crude extracts was done as described in [13]. Total 
protein concentration was measured by the method of Zamenhoff [37]. 
Samples containing 50 u.g of crude extract were loaded onto 7.5% 
SDS polyacrylamide gels (SDS-PAGE). All following procedures 
have been described in [38]. Alternatively, crossreacting proteins 
were detected by fluorescence using the kit of Tropix (Serva/Heidel-
berg) according to the recommendations of the manufacturer. Mono-
clonal antibodies against the hemagglutinin epitope used were ob-
tained from BAbCO (Berkeley, CA, USA). 
Fig. 1. A: Schematic representation of the domain structure of Pkclp. 'P' indicates the pseudosubstrate site. The nomenclature for the other 
domains is explained in the text. Bars below indicate the two DAG binding domains in the Cl region. A comparison of the yeast Pkclp se-
quence with the homologous proteins from other organisms in the putative DAG binding domains is depicted below. B: Model of the DAG 
binding domain adapted from the mammalian homologue according to [39]. As an activator, phorbol ester is placed in the binding groove 
where DAG binding is supposed to take place. Cysteine residues exchanged for serines in this work are boxed and marked by arrows. 
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3. Results and discussion 
3.1. Mutagenesis of putative DAG binding sites 
Alignments of the deduced amino acid sequences of Pkclp 
from yeast to a variety of other organisms shows a conserva-
tion of key residues that have been demonstrated to take part 
in the formation of zinc binding. This in turn is necessary for 
the correct folding of a DAG binding groove [39] (see also 
Fig. IB). In fact, two of these DAG binding motifs are lo-
cated adjacent to each other in the yeast enzyme, a region 
which in analogy to its mammalian counterparts is designated 
'Cl ' (Fig. 1A). By in vitro mutagenesis, we exchanged two 
critical cysteine residues, essential for the coordination of 
Zn2+, in each of these regions for serines in yeast Pkclp 
(i.e. residues 434, 437, 514 and 517, according to the number-
ing of the yeast enzyme, counting the initiating methionine). 
As the PCR-based method of Boles and Miosga [40] was used 
for mutagenesis, the entire Xbal fragment used to replace the 
wild-type sequence was sequenced to confirm that no other 
exchanges were introduced (see Section 2 for cloning details). 
The wild-type and mutant PKC1 alleles were introduced on 
CENIARS plasmids (pHPS13 and pHPS23, respectively; see 
Section 2) into a diploid strain heterozygous for a deletion in 
pkcl. Transformants were selected for leucine prototrophy, 
sporulated, tetrads dissected and segregants were again al-
lowed to grow on medium lacking leucine. In both cases via-
ble segregants were obtained, indicating that the mutations 
introduced did not lead to a complete lack of Pkclp function. 
Strains not carrying a PKC1 allele on a plasmid segregated 
2:2 for viability even in the presence of osmotic stabilizers. 
Thus, PKC1 is essential for viability in the yeast strains em-
ployed here. A haploid deletion construct with a GAL1I10 
promoter fusion of PKC1 integrated at the URA3 locus was 
not very useful in our hands, as after transfer from galactose 
to glucose media the strain continued to grow on solid media 
Fig. 3. Western blot detecting the HA-tagged Pkclp. As a recipient 
strain, VW1A was used, which was either not transformed (wt 
—HA), transformed with the wild-type PKC1 version carrying an 
HA tag at the N-terminal end (wt +HA; pHPS30), or transformed 
with the mutant pkcl containing the cysteine to serine exchanges in 
the two putative DAG binding domains and an HA tag at the N-
terminal end (mut +HA; pHPS29). Monoclonal antibodies against 
hemagglutinin were used for detection by fluorescence. The filter 
was exposed to a Fuji RX-film for 20 min. The band corresponding 
to Pkclp is indicated by an arrow. The second arrow points to a 
band reacting non-specifically (ns) in all extracts. 
even after replica-plating twice on glucose [13]. Thus, a very 
low Pkclp activity seems to be sufficient to retain viability. 
3.2. Growth characteristics of the mutant alleles in a pkcl 
deletion mutant 
As the haploid transformants carrying the mutated PKC1 
allele were viable on our standard media, we tested growth on 
plates containing several compounds known to affect the 
Pkclp pathway in yeast (Fig. 2). As transformants carrying 
the wild-type allele, the ones with the mutant allele were cap-
able of growth in the presence of staurosporine. However, 
the latter were sensitive for growth in the presence of caffeine, 
calcofluor white and SDS. Thus, several phenotypes typical 
for defects in the Pkclp signal transduction pathway could be 
observed in the mutants. This could be due either directly to a 
lack of function introduced by the amino acid exchanges or to 
an increased instability of the mutant protein. To exclude the 
latter possibility, we constructed fusions of Pkclp with an N-
terminal hemagglutinin tag. Again, the same fusion was con-
structed with a wild-type PKC1 allele. Western analysis con-
firmed that the stability of the mutant protein does not nota-
bly differ from that of the wild-type (Fig. 3). Thus, the 
phenotypes observed can be attributed to a functional differ-
ence in the protein introduced by the amino acid exchanges. 
Fig. 2. Phenotypes of a pkcl deletion mutant transformed with the 
pkcl allele affected in a putative DAG binding site. Cells of trans-
formants with CENIARS plasmids carrying either the wild-type al-
lele of PKC1 (wt; pHPS13) or the allelele with the cysteine residues 
exchanged for serines in both DAG binding domains (mut; 
pHPS23; compare Fig. 1) were plated on the indicated media and 
allowed to grow for 3 days at 30°C. 
3.3. Conclusions 
Although biochemical data indicated that yeast Pkclp is 
activated neither by DAG nor by phorbol esters, our data 
suggest that the conserved DAG binding sites serve a critical 
function. Thus, distortion of these sites leads to sensitivity to a 
variety of compounds known to affect the signal transduction 
pathway mediated by Pkclp. However, it is noteworthy that 
the sensitivity to staurosporine was not affected. Together 
with the fact that the mutant allele restored viability to the 
pkcl deletion strain this points to a dual role of Pkclp in 
yeast, where only one of the functions is dependent on 
DAG binding. This further supports similar conclusions 
drawn from genetic studies aimed at the interaction of 
Pkclp with other yeast proteins [1]. Whether the binding do-
222 J.J. Jacoby et al.lFEBS Letters 417 (1997) 219-222 
main really interacts with D A G , an analogue of it or even 
with other yeast proteins, as suggested for R h o l p [20], re-
mains to be elucidated. 
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